title: [Pharmacological treatment of COPD. Where are we now?].
abstract: Current clinical guidelines recommend a step-wise approach to the pharmacological treatment of chronic obstructive pulmonary disease (COPD), with drugs being added according to the severity of airflow obstruction, symptoms, and the number of acute exacerbations in patients with severe disease. However, greater knowledge of the physiopathogenesis of this disease has led to COPD being considered a heterogeneous process in which therapeutic decisions should not be based exclusively on the results of spirometry. Treatment is increasingly individualized according to the patient's characteristics. The present article reviews the scientific evidence on the aims of treatment in COPD and the benefits achieved by the various pharmacological options available.
authors.affiliation: Servicio de Neumología, Hospital Clínico San Carlos, Universidad Complutense, Madrid, España. med010161@saludalia.com
authors.forename: Myriam
authors.initials: M
authors.lastname: Calle Rubio
authors.forename: Celia
authors.initials: C
authors.lastname: Pinedo Sierra
authors.forename: Juan Luis
authors.initials: JL
authors.lastname: Rodríguez Hermosa
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001993:Bronchodilator Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D019468:Disease Management; D018450:Disease Progression; D017079:Exercise Tolerance; D006801:Humans; D010102:Oxygen Inhalation Therapy; D058988:Phosphodiesterase 4 Inhibitors / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D057285:Precision Medicine; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy; D016032:Randomized Controlled Trials as Topic; D016540:Smoking Cessation
chemical_list: D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D001993:Bronchodilator Agents; D058988:Phosphodiesterase 4 Inhibitors